Exploring the Prognostic Potential of Genomic Features in Over 1400 Gliomas

Brito Dantas^*
*Correspondence: Brito Dantas, Department of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA, Email:

Description

Gliomas are a heterogeneous group of primary brain tumors characterized by diverse genetic alterations. Understanding the genomic features that contribute to their prognosis and recurrence is crucial for improving patient outcomes. In recent years, significant progress has been made in unraveling the prognostic value of genomic features in gliomas. Among these features, the SBS11 mutational signature has emerged as a promising candidate associated with glioma recurrence. This article aims to provide a systematic evaluation of the prognostic value of genomic features in a large cohort of over 1400 gliomas, with a specific focus on the association between the SBS11 mutational signature and glioma recurrence. The study cohort comprises a diverse collection of glioma samples, including both low-grade and high-grade tumors, obtained from multiple institutions.

Genomic profiling was performed using state-of-the-art sequencing technologies, allowing comprehensive analysis of various genetic alterations, including single-base substitutions. The association between specific mutational signatures and clinical outcomes, particularly glioma recurrence, was investigated using rigorous statistical analyses. In this systematic evaluation, we observed a significant association between the SBS11 mutational signature and glioma recurrence. The SBS11 mutational signature, characterized by specific patterns of single-base substitutions, was found to be more prevalent in recurrent gliomas compared to non-recurrent cases. Moreover, its presence was associated with worse overall survival and progression-free survival rates, highlighting its potential as a prognostic marker.

Further sub-analysis focusing on low-grade gliomas revealed an even stronger association between the SBS11 mutational signature and poor prognosis. Patients with low-grade gliomas exhibiting the SBS11 mutational signature had a significantly higher risk of disease progression and shorter overall survival, underscoring the relevance of this genomic feature in predicting outcomes specifically for this subgroup. The identification of the SBS11 mutational signature as a prognostic marker associated with glioma recurrence has significant clinical implications. It not only provides insights into the underlying biology of gliomas but also enables risk stratification and personalized treatment approaches for patients. Understanding the mechanisms driving the SBS11 mutational signature and its functional consequences on glioma biology will be essential for developing targeted therapeutic strategies [1,2].

This systematic evaluation of genomic features in a large cohort of over 1400 gliomas highlights the significant association between the SBS11 mutational signature and glioma recurrence. The findings underscore the importance of incorporating genomic information into clinical practice for improved prognostication and treatment decision-making in glioma patients. Further research efforts should focus on elucidating the biological mechanisms underlying the SBS11 mutational signature and exploring its potential as a therapeutic target in the future. Low-Grade Gliomas (LGGs) are a subgroup of primary brain tumors characterized by their slow-growing nature and relatively favorable prognosis compared to high-grade gliomas.

However, within the LGG category, there exists considerable heterogeneity in terms of clinical outcomes and response to treatment. Consequently, the ability to accurately predict prognosis and identify high-risk LGGs with shortened survival is of paramount importance. Recent research has shed light on the prognostic value of the SBS11 mutational signature, providing valuable insights into the identification and management of LGG patients at higher risk of adverse outcomes. This article aims to explore the predictive significance of the SBS11 mutational signature in LGGs and its potential for identifying highrisk tumors with shortened survival [3].

A comprehensive study was conducted, involving a well-characterized cohort of LGG patients with detailed clinical and genomic information. Genomic profiling was performed to detect the presence of the SBS11 mutational signature, along with other relevant genetic alterations. Prognostic analyses were carried out to evaluate the association between the SBS11 mutational signature and clinical outcomes, including overall survival and progression-free survival. The results of this study demonstrate a strong correlation between the SBS11 mutational signature and worse prognosis in LGGs. Patients whose tumors exhibited the SBS11 mutational signature had significantly shorter overall survival and progression-free survival compared to those without the signature. Importantly, the SBS11 mutational signature was found to be an independent prognostic factor, capable of predicting outcomes even after accounting for other clinicopathological variables [4].

Subgroup analysis revealed that the SBS11 mutational signature was particularly predictive of adverse outcomes in LGGs. Patients with the SBS11 mutational signature had a higher risk of disease progression and poorer overall survival rates, indicating the presence of a distinct high-risk subset within the LGG population. The identification of the SBS11 mutational signature as a prognostic predictor in LGGs has significant clinical implications. It enables the identification of high-risk LGG patients who may benefit from more aggressive treatment strategies and closer surveillance. The SBS11 mutational signature could serve as a valuable tool in personalized medicine, aiding clinicians in tailoring treatment plans and optimizing patient care.

Understanding the underlying biological mechanisms driving the SBS11 mutational signature may provide insights into the molecular pathways involved in LGG progression and aggressiveness. This knowledge could open avenues for the development of targeted therapies aimed at mitigating the adverse effects of the SBS11 mutational signature and improving patient outcomes. The SBS11 mutational signature represents a powerful prognostic predictor in low-grade gliomas, allowing for the identification of high-risk tumors with shortened survival. Its association with worse clinical outcomes highlights its potential as a valuable tool in clinical practice, facilitating risk stratification and personalized treatment decisions. Further research is warranted to elucidate the biological underpinnings of the SBS11 mutational signature and explore its therapeutic implications for improving the prognosis of LGG patients [5].

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zhang, Baifeng, Weiqing Wan, Zibo Li and Zhixian Gao, et al. "A prognostic risk model for glioma patients by systematic evaluation of genomic variations." Iscience 25 (2022): 105681.

Google Scholar, Crossref, Indexed at

2. Ozair, Ahmad, Vivek Bhat, Reid S. Alisch and Atulya A. et al. "DNA methylation and histone modification in low-grade gliomas: Current understanding and potential clinical targets." Cancers 15 (2023): 1342.

Google Scholar, Crossref, Indexed at

3. Wang, Ronglin, Yuqian Li, Gang Zhu and Bo Tian, et al. "Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway." Neuropsychiatr Dis Treat (2017): 1805-1813.

Google Scholar, Crossref, Indexed at

4. Zhang, Jun-Xia, Lei Han, Zhao-Shi Bao and Ying-Yi Wang, et al. "HOTAIR, a cell cycle–associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma." J Neurooncol 15 (2013): 1595-1603.

Google Scholar, Crossref, Indexed at

5. Yan, Jing, Yuanshen Zhao, Yinsheng Chen and Weiwei Wang, et al. "Deep learning features from diffusion tensor imaging improve glioma stratification and identify risk groups with distinct molecular pathway activities." EBioMedicine 72 (2021): 103583.

Google Scholar, Crossref, Indexed at